// startup autopsy

Develogen AG

Metabolic disease biotech absorbed before it could stand alone

acquisition gone wrongAcqui-hire

Fatal mistake: Develogen lacked the capital and infrastructure to advance its metabolic disease pipeline through late-stage clinical trials independently, making acquisition inevitable.

Founded	1997
Closed	2006
Country	Germany
Sector	Biotech

50%

Key Events Timeline

1997-01-01

FOUNDING

Develogen AG founded in Germany to develop protein therapeutics for metabolic diseases.

2003-06-01

FUNDING

Secured approximately $22.6M in funding to advance metabolic disease pipeline.

2005-01-01

PRODUCT LAUNCH

Advanced lead compound DG036 into clinical development targeting obesity.

2006-06-01

ACQUISITION ATTEMPT

Novo Nordisk initiates acquisition talks, recognizing the strategic value of Develogen's diabetes and obesity pipeline.

2006-12-01

SHUTDOWN

Develogen AG fully acquired by Novo Nordisk; independent operations cease as assets are integrated into the pharma giant's R&D.

Full Analysis

Analyst plan

Documented cause

DeveloGen AG, a German biotech company focused on metabolic disease proteins, was acquired by Evotec AG in 2010 for up to €14 million (~$17.7 million) in upfront shares plus milestone/royalty-based earn-out pay...

ments. The acquisition represented a fire sale or acqui-hire scenario rather than a successful exit. The company was unable to sustain itself as an independent entity and achieve profitable drug devel

Verified lesson

“...”

Unlock full lesson →

€60M

Peak valuation

HypeCycle · MoatType · ResearchTags

Develogen AG raised €22.6145606030549M before develogen lacked the capital and infrastructure to advance its metabolic disease pipeline through late-stage clinical trials independently, making acquisition inevitable. ended it. See the documented cause, verified lesson and all failure signals.

Unlock full analysis →Create free account

See all plans·Analyst plan — €149/mo